OSR Holdings Inc

OSRH

0.459USD

+0.019+4.36%

Close 03/27, 16:00（ET）Quotes delayed by 15 min

OSR Holdings Inc's Score

Industry at a Glance

Industry Ranking

210 / 391

Overall Ranking

435 / 4546

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

OSR Holdings Inc Highlights

StrengthsRisks

OSR Holdings, Inc. is a global healthcare company, dedicated to advancing healthcare outcomes and improving the quality of life for people and their families. The Company is focused on building and developing a portfolio of transformative therapies and healthcare solutions. The Company's operating businesses (through its three wholly owned subsidiaries) include developing oral immunotherapies for the treatment of cancer, developing design-augmented biologics for age-related and other degenerative diseases and neurovascular intervention medical device and systems distribution in Korea. The Company’s subsidiary, Vaximm’s flagship asset, VXM01, is a late clinical-stage (NCT037500701) immuno-oncology candidate for glioblastoma. Vaximm has three clinical and pre-clinical drug candidates targeting diseases ranging from glioblastoma to gastrointestinal stromal tumor to ocular diseases. The Company has operations in Europe and South Korea.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Turnaround to Loss

The company's performance has turned to a loss, with the latest annual loss of USD .

Overvalued

The company’s latest PE is 0.15, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 236.43K shares, decreasing 93.35% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 54.40K shares of this stock.

Analyst Rating

Based on 1 analysts

Buy

Current Rating

10.000

Target Price

+2102.16%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of OSR Holdings Inc is 5.72, ranking 328 out of 391 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

5.72

Change

0



Financials

5.25

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.47

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.84

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

5.95

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.08

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of OSR Holdings Inc is 6.10, ranking 327 out of 391 in the Biotechnology & Medical Research industry. Its current P/E ratio is 0.15, which is 83.67% below the recent high of 0.28 and 30175.11% above the recent low of -46.05.

Score

Industry at a Glance

Previous score

6.10

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 210/391

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of OSR Holdings Inc is 8.00, ranking 163 out of 391 in the Biotechnology & Medical Research industry. The average price target is 10.00, with a high of 10.00 and a low of 10.00.

Score

Industry at a Glance

Previous score

8.00

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

No price momentum score is currently available for OSR Holdings Inc. The Biotechnology & Medical Research industry's average is 6.55.

Score

Industry at a Glance

Previous score

0.00

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-03-26

Score

Industry at a Glance

Previous score

3.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

BCM Europe AG

7.53M

--

Bellevue Capital Management LLC

3.12M

--

Bellevue Global Life Sciences Investors LLC

1.33M

--

Geode Capital Management, L.L.C.

55.59K

+471.18%

The Vanguard Group, Inc.

Star Investors

54.40K

+45.56%

Park (Jin Whan)

20.00K

--

Mint Tower Capital Management B.V.

7.50K

--



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of OSR Holdings Inc is 1.27, ranking 325 out of 391 in the Biotechnology & Medical Research industry. The company's beta value is 0.00. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.

OSR Holdings Inc

OSRH

4.37 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

BioCryst Pharmaceuticals Inc

BCRX

8.59 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

8.47 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

AnaptysBio Inc

ANAB

8.40 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

IQVIA Holdings Inc

IQV

8.31 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Madrigal Pharmaceuticals Inc

MDGL

8.30 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment